Precise editing of human hematopoietic stem and progenitor cells (HSPC) is of interest both for the treatment of genetic disorders and for disease modeling. The advent of CRISPR/Cas has made such editing possible, however, current strategies have remained limited to 10-20% efficiency. Uses requiring purity thus need to include selection markers. This also limits donor selection to adeno-associated virus (AAV), as single stranded oligonucleotide donors (ssODNs) are not long enough to incorp...